| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.0M | — | — |
| R&D Expense | $19.6M | — | +47.8% |
| SG&A Expense | $3.7M | — | +14.3% |
| Operating Income | -$13.3M | — | +19.3% |
| Income Tax | $0 | — | — |
| Net Income | -$12.5M | — | +21.6% |
| EPS (Basic) | -$8.07 | — | +22.9% |
| EPS (Diluted) | -$8.07 | — | +22.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $26.8M | — | +47.8% |
| Short-term Investments | $49.2M | — | — |
| Current Assets | $81.9M | — | — |
| Total Assets | $84.5M | — | — |
| Current Liabilities | $10.4M | — | — |
| Total Liabilities | $10.7M | — | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$59.7M | — | — |
| Capital Expenditures | $131K | — | — |
| Investing Cash Flow | $7.6M | — | — |
| Financing Cash Flow | $63.9M | — | — |
| Free Cash Flow | -$59.9M | — | — |
| Stockholders' Equity | -$183.1M | -7.0% | -49.5% |